MUMBAI, India, Nov. 21 -- Intellectual Property India has published a patent application (202517097939 A) filed by Lung Biotechnology Pbc, Maryland, U.S.A., on Oct. 10, for 'ccl20 promoter-regulated gene expression.'
Inventor(s) include Exline, Colin.
The application for the patent was published on Nov. 21, under issue no. 47/2025.
According to the abstract released by the Intellectual Property India: "The present disclosure relates to CCL20 promoters derived from the regulatory region of the CCL20 gene that stimulate gene expression in response to inflammation. These CCL20 promoters, which can be stimulated by an endogenous or exogenous cytokine, can be used to control the timing of the expression of a heterologous gene. The present disclosure also relates to expression cassettes or vectors comprising the CCL20 promoters of the present disclosure operably linked to a nucleic acid sequence encoding, e.g., a polypeptide of interest, as well as delivery systems (e.g., viral particles, lipid vesicles, or nanoparticles) or cells comprising such expression cassettes or vectors. The present disclosure also relates to the use of the promoters, expression cassettes, vectors, delivery systems, or cells in the treatment of diseases related to inflammation, or for recombinant gene expression."
The patent application was internationally filed on Mar. 20, 2024, under International application No.PCT/US2024/020757.
Disclaimer: Curated by HT Syndication.
